Last reviewed · How we verify
avanafil 200mg — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
avanafil 200mg (avanafil 200mg) — VIVUS LLC.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| avanafil 200mg TARGET | avanafil 200mg | VIVUS LLC | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- avanafil 200mg CI watch — RSS
- avanafil 200mg CI watch — Atom
- avanafil 200mg CI watch — JSON
- avanafil 200mg alone — RSS
Cite this brief
Drug Landscape (2026). avanafil 200mg — Competitive Intelligence Brief. https://druglandscape.com/ci/avanafil-200mg. Accessed 2026-05-14.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab